TSHA — Taysha Gene Therapies, Inc.

Summary of Taysha Gene Therapies, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $109 million for the year ended December 31, 2025, compared to a net loss of $89.3 million in 2024. Loss per share was $0.34, slightly improved from $0.36 per share in the previous year.
• Research and Development Expenses: Increased to $86.4 million from $66 million in 2024, primarily due to higher compensation and clinical trial costs.
• General and Administrative Expenses: Rose to $33.9 million from $29 million, attributed to increased compensation and legal fees.
• Cash Position: As of December 31, 2025, Taysha had $319.8 million in cash and equivalents, with an additional $50 million raised through an equity offering to support potential commercialization efforts.

2. Strategic Updates and Business Highlights

• Clinical Progress: Positive data from the REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome, showing a 100% response rate in initial patients. The FDA granted Breakthrough Therapy designation and aligned on pivotal trial designs.
• Pivotal Trial Initiation: The REVEAL pivotal trial commenced in 2025, with multiple patients dosed and ongoing enrollment across sites. The ASPIRE trial received FDA clearance to evaluate safety in younger patients.
• Market Research Insights: Indicated strong demand for TSHA-102, with caregivers and clinicians favoring intrathecal administration due to its familiarity and accessibility compared to more invasive methods.

3. Forward Guidance and Outlook

• Regulatory Pathway: Taysha aims to submit a Biologics License Application (BLA) in 2026, contingent on ongoing clinical data and FDA alignment. The company is on track to complete dosing for both REVEAL and ASPIRE studies in 2026.
• Commercial Readiness: Continued development of internal commercial infrastructure, including the appointment of Brad Martin as Senior VP of Market Access and Value, to prepare for potential product launch.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The rise in net loss and operational expenses raises concerns about financial sustainability as the company progresses toward commercialization.
• Regulatory Risks: While the FDA has been supportive, any changes in regulatory expectations or delays in trial results could impact timelines for BLA submission.
• Competitive Landscape: The company faces competition from other gene therapies, such as Neurogene's product, which has raised questions about the clinical meaningfulness of six-month data endpoints.

5. Notable Q&A Insights

• Intrathecal Administration: Clinicians and caregivers are comfortable with the intrathecal route, viewing it as less invasive and more practical for broader patient access.
• Market Access Strategy: The company plans to engage early with payers to educate them on the disease and clinical data, leveraging relationships built by new leadership in market access.
• Data Pooling: Taysha will pool data from the Phase 1/2 and pivotal trials to enhance the robustness of their BLA submission, which the FDA has agreed to support.
• Patient Enrollment: Enrollment for pivotal studies is progressing well, with expectations to meet timelines for data analysis and reporting.

This summary encapsulates Taysha Gene Therapies' financial performance, strategic initiatives, outlook, and challenges as discussed during the earnings call.